Brasil, S, Allocca, M, Magrinho, SCM, Santos, I, Raposo, M, Francisco, R et al.. Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG). Int J Mol Sci. 2022;23 (15):. doi: 10.3390/ijms23158725. PubMed PMID:35955863 .
Pearson, C, Schapiro, L, Pearson, SD. The next generation of rare disease drug policy: ensuring both innovation and affordability. J Comp Eff Res. 2022; :. doi: 10.2217/cer-2022-0120. PubMed PMID:35946484 .
Blonda, A, Denier, Y, Huys, I, Kawalec, P, Simoens, S. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries. Front Pharmacol. 2022;13 :902150. doi: 10.3389/fphar.2022.902150. PubMed PMID:35928274 PubMed Central PMC9343828.
Seki, K, Suzuki, H, Abe, S, Saotome, C. Lifecycle management of orphan drugs approved in Japan. Orphanet J Rare Dis. 2022;17 (1):299. doi: 10.1186/s13023-022-02456-w. PubMed PMID:35906686 PubMed Central PMC9336109.
Abozaid, GM, Kerr, K, McKnight, A, Al-Omar, HA. Criteria to define rare diseases and orphan drugs: a systematic review protocol. BMJ Open. 2022;12 (7):e062126. doi: 10.1136/bmjopen-2022-062126. PubMed PMID:35906057 .
Xiang, Z, Jiang, W, Yan, B, Jiang, J, Zheng, H. Current status and trend of clinical development of orphan drugs in China. Orphanet J Rare Dis. 2022;17 (1):294. doi: 10.1186/s13023-022-02440-4. PubMed PMID:35897012 PubMed Central PMC9327367.
Mazzucato, M, Minichiello, C, Visonà Dalla Pozza, L, Vianello, A, Toto, E, De Lorenzi, M et al.. [The impact of the use of treatments not included in the reimbursement classes in the care of rare patients: a real world study.]. Recenti Prog Med. ;113 (7):440-450. doi: 10.1701/3850.38339. PubMed PMID:35852080 .
Casali, PG, Provenzano, S, Trama, A. [The problem of rare cancers.]. Recenti Prog Med. ;113 (7):430-433. doi: 10.1701/3850.38337. PubMed PMID:35852078 .
Crisafulli, S, Trifirò, G. [The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs.]. Recenti Prog Med. ;113 (7):425-429. doi: 10.1701/3850.38336. PubMed PMID:35852077 .
Costa, E, Grimaldi, G, Del Grosso, V, Isgrò, A, Genazzani, A. [Access to medicines for rare diseases: regulatory aspects and public health priorities.]. Recenti Prog Med. ;113 (7):415-424. doi: 10.1701/3850.38335. PubMed PMID:35852076 .
Costa, E, Magrini, N. [Harmonizing development, approval and access of drugs for rare diseases in Europe.]. Recenti Prog Med. ;113 (7):407-410. doi: 10.1701/3850.38333. PubMed PMID:35852074 .
Wu, X, Xu, W, Yu, M, Zhang, F, Wang, H. Clinical trials of orphan drugs in China over the decade 2012-2022: Opportunities and challenges. Pharmacol Res. 2022;182 :106349. doi: 10.1016/j.phrs.2022.106349. PubMed PMID:35835367 .
Stafinski, T, Glennie, J, Young, A, Menon, D. HTA decision-making for drugs for rare diseases: comparison of processes across countries. Orphanet J Rare Dis. 2022;17 (1):258. doi: 10.1186/s13023-022-02397-4. PubMed PMID:35804398 PubMed Central PMC9264608.
Zhou, N, Ji, H, Li, Z, Hu, J, Xie, JH, Feng, YH et al.. Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia. Front Public Health. 2022;10 :861067. doi: 10.3389/fpubh.2022.861067. PubMed PMID:35784205 PubMed Central PMC9247336.
Gabison, EE, Guindolet, D. Neurotrophic Keratitis: A rare disease that requires proactive screening and orphan drug treatments. Ocul Surf. 2022;25 :154. doi: 10.1016/j.jtos.2022.06.008. PubMed PMID:35781074 .
Partin, C. Rarely mentioned: how we arrived at the quantitative definition of a rare disease. Proc (Bayl Univ Med Cent). 2022;35 (4):498-504. doi: 10.1080/08998280.2022.2048613. PubMed PMID:35754591 PubMed Central PMC9196794.
Mohammadshahi, M, Olyaeemanesh, A, Ehsani-Chimeh, E, Mobinizadeh, M, Fakoorfard, Z, Akbari Sari, A et al.. Methods and criteria for the assessment of orphan drugs: a scoping review. Int J Technol Assess Health Care. 2022;38 (1):e59. doi: 10.1017/S0266462322000393. PubMed PMID:35730573 .
Fontrier, AM. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations. Soc Sci Med. 2022;306 :115119. doi: 10.1016/j.socscimed.2022.115119. PubMed PMID:35700552 .
Rawson, NSB. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?. Orphanet J Rare Dis. 2022;17 (1):218. doi: 10.1186/s13023-022-02390-x. PubMed PMID:35698235 PubMed Central PMC9190095.
Gandini, E, Marcou, G, Bonachera, F, Varnek, A, Pieraccini, S, Sironi, M et al.. Molecular Similarity Perception Based on Machine-Learning Models. Int J Mol Sci. 2022;23 (11):. doi: 10.3390/ijms23116114. PubMed PMID:35682792 PubMed Central PMC9181189.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.